Showing 4211-4220 of 4925 results for "".
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- A “C” Change: Introducing Exuviance's New Vitamin C Serum Capsuleshttps://practicaldermatology.com/news/a-c-change-introducing-exuviances-new-vitamin-c-serum-capsules/2458250/Coming this summer, Exuviance’s AF Vitamin C20 serum capsules promise maximum delivery of actives. Unlike many existing products, Exuviance AF Vitamin C20 Serum comes in capsule form. Other types of packaging expose vitamin C to light, air, o
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- New Research Closes In On Personalized AD Therapyhttps://practicaldermatology.com/news/new-research-closes-in-on-personalized-therapy-for-ad/2458254/New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Cutanea Unveils Aktipak Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patientshttps://practicaldermatology.com/news/cutanea-unveils-aktipak-gel-35-convenient-acne-treatment-for-on-the-go-patients/2458260/Cutanea Life Sciences, Inc. (CLS) introduced Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The product is available through dermatologists' offices. Aktipak is a portable, freshly mixed, p
- BTL Aesthetics To Unveil New Ultra Femme 360° Technology for Vaginal Rejuvenation at AADhttps://practicaldermatology.com/news/btl-aesthetics-to-unveil-new-ultra-femme-360-technology-for-vaginal-rejuvenation-at-aad/2458263/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- Sun Pharma to Present Data from Tildrakizumab Clinical Development Program at 2017 AAD Meetinghttps://practicaldermatology.com/news/sun-pharma-to-present-data-from-tildrakizumab-clinical-development-program-at-2017-aad-meeting/2458266/Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, at the 2017 Annual America